AML
MCID: LKM061
MIFTS: 73

Leukemia, Acute Myeloid (AML) malady

Categories: Genetic diseases, Rare diseases, Cancer diseases, Immune diseases, Blood diseases

Aliases & Classifications for Leukemia, Acute Myeloid

Aliases & Descriptions for Leukemia, Acute Myeloid:

Name: Leukemia, Acute Myeloid 54 38
Acute Myeloid Leukemia 38 12 50 24 66 29 41 14
Acute Myelogenous Leukemia 12 50 24 14
Leukemia, Acute Myelogenous 24 66 13
Acute Myeloblastic Leukemia 12 66
Leukemia, Myelocytic, Acute 12 69
Aml 24 66
Leukemia, Acute Myeloid, Reduced Survival in, Somatic 54
Myeloid Leukemia, Acute, M4/m4eo Subtype, Somatic 54
Leukemia, Acute Myeloid, Somatic 54
Acute Non-Lymphoblastic Leukemia 66
Acute Non-Lymphocytic Leukemia 66
Aml - Acute Myeloid Leukemia 12
Acute Myelocytic Leukemia 66
Leukemia, Myeloid, Acute 42
Leukemia, Acute Myeloie 54

Characteristics:

HPO:

32
leukemia, acute myeloid:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 54 601626
Disease Ontology 12 DOID:9119
ICD9CM 35 205.0
MeSH 42 D015470
NCIt 47 C27753 C3171
UMLS 69 C0023467

Summaries for Leukemia, Acute Myeloid

MedlinePlus : 41 leukemia is cancer of the white blood cells. white blood cells help your body fight infection. your blood cells form in your bone marrow. in leukemia, however, the bone marrow produces abnormal white blood cells. these cells crowd out the healthy blood cells, making it hard for blood to do its work. in acute myeloid leukemia (aml), there are too many of a specific type of white blood cell called a myeloblast. aml is the most common type of acute leukemia in adults. this type of cancer usually gets worse quickly if it is not treated. possible risk factors include smoking, previous chemotherapy treatment, and exposure to radiation. symptoms of aml include: fever shortness of breath easy bruising or bleeding bleeding under the skin weakness or feeling tired weight loss or loss of appetite tests that examine the blood and bone marrow diagnose aml. treatments include chemotherapy, other drugs, radiation therapy, stem cell transplants, and targeted therapy. targeted therapy uses substances that attack cancer cells without harming normal cells. once the leukemia is in remission, you need additional treatment to make sure that it does not come back. nih: national cancer institute

MalaCards based summary : Leukemia, Acute Myeloid, also known as acute myeloid leukemia, is related to acute leukemia and acute myeloblastic leukemia without maturation, and has symptoms including acute myeloid leukemia, angina pectoris and chest pain. An important gene associated with Leukemia, Acute Myeloid is JAK2 (Janus Kinase 2), and among its related pathways/superpathways are Acute myeloid leukemia and Pathways in cancer. The drugs Leukine and Lynparza have been mentioned in the context of this disorder. Affiliated tissues include Blood and Blood, and related phenotypes are cellular and growth/size/body region

Disease Ontology : 12 A myeloid leukemia that is characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells.

NIH Rare Diseases : 50 acute myeloid leukemia (aml) is a cancer that affects the blood and bone marrow. conditions are generally called "acute" when they develop quickly and have an aggressive course. the signs and symptoms of aml vary but may include easy bruising; bone pain or tenderness; fatigue; fever; frequent nosebleeds; bleeding from the gums; shortness of breath; and/or weightloss. aml is one of the most common types of leukemia among adults and is rarely diagnosed in people under age 40. there are many potential causes of aml such as certain blood disorders, inherited syndromes, environmental exposures, and drug exposures; however, most people who develop aml have no identifiable risk factor. treatment may include a combination of chemotherapy, radiation therapy, bone marrow transplant and/or other drug therapy. last updated: 10/29/2015

UniProtKB/Swiss-Prot : 66 Leukemia, acute myelogenous: A subtype of acute leukemia, a cancer of the white blood cells. AML is a malignant disease of bone marrow characterized by maturational arrest of hematopoietic precursors at an early stage of development. Clonal expansion of myeloid blasts occurs in bone marrow, blood, and other tissue. Myelogenous leukemias develop from changes in cells that normally produce neutrophils, basophils, eosinophils and monocytes.

Wikipedia : 71 Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid... more...

Description from OMIM: 601626

Related Diseases for Leukemia, Acute Myeloid

Diseases in the Myeloid Leukemia family:

Leukemia, Acute Myeloid Acute Myeloid Leukemia, Flt3-Related
Acute Myeloid Leukemia, Kit-Related Npm1-Related Acute Myeloid Leukemia
Inherited Acute Myeloid Leukemia Acute Myeloid Leukemia with T(9;11)(p22;q23)
Acute Myeloid Leukemia with T(6;9)(p23;q34)

Diseases related to Leukemia, Acute Myeloid via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 78)
id Related Disease Score Top Affiliating Genes
1 acute leukemia 32.3 FLT3 MLLT10
2 acute myeloblastic leukemia without maturation 12.5
3 cytogenetically normal acute myeloid leukemia 12.5
4 core binding factor acute myeloid leukemia 12.5
5 familial acute myeloid leukemia with mutated cebpa 12.4
6 acute myeloblastic leukemia with maturation 12.3
7 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 12.3
8 familial platelet disorder with propensity to acute myelogenous leukemia 12.2
9 therapy related acute myeloid leukemia and myelodysplastic syndrome 12.1
10 acute myeloid leukemia with t(9;11)(p22;q23) 12.1
11 acute myeloid leukemia with t(8;16)(p11;p13) translocation 12.1
12 acute myeloid leukemia with t(6;9)(p23;q34) 12.1
13 acute myeloid leukemia with minimal differentiation 12.1
14 cebpa-associated familial acute myeloid leukemia 12.1
15 inherited acute myeloid leukemia 12.0
16 acute myeloid leukemia with inv3(p21;q26.2) or t(3;3)(p21;q26.2) 12.0
17 acute myeloid leukemia with t(8;21)(q22;q22) translocation 12.0
18 acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent 12.0
19 acute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitor 12.0
20 acute myeloid leukemia and myelodysplastic syndromes related to radiation 12.0
21 acute myeloid leukemia with cebpa somatic mutations 12.0
22 megakaryoblastic acute myeloid leukemia with t(1;22)(p13;q13) 12.0
23 acute myeloid leukemia with recurrent genetic anomaly 12.0
24 acute myeloid leukemia with npm1 somatic mutations 12.0
25 acute myeloid leukemia with 11q23 abnormalities 12.0
26 aml with myelodysplasia-related features 11.8
27 platelet disorder, familial, with associated myeloid malignancy 11.8
28 leukemia 11.4
29 megakaryocytic leukemia 11.1
30 acute non lymphoblastic leukemia 11.1
31 acute myeloid leukemia, flt3-related 11.0
32 cranioectodermal dysplasia 1 10.9 CEBPA CHIC2 DNMT3A ETV6 FLT3 GATA2
33 agammaglobulinemia 8, autosomal dominant 10.7 CEBPA DNMT3A ETV6 FLT3 GATA2 IDH1
34 hemophagocytic lymphohistiocytosis 10.7 ETV6 FLT3 GATA2 JAK2 KIT MLLT10
35 milker's nodule 10.7 CEBPA DNMT3A ETV6 FLT3 KIT NPM1
36 liver disease 10.7 CEBPA ETV6 FLT3 JAK2 KIT MLLT10
37 acute respiratory distress syndrome 10.7 CEBPA FLT3 GATA2 JAK2 KIT NPM1
38 acute lymphocytic leukemia 10.6 CEBPA ETV6 FLT3 JAK2 KIT MLLT10
39 phosphoserine phosphatase deficiency 10.6 ETV6 FLT3 GATA2 MLLT10 NUP214 PICALM
40 familial hyperaldosteronism 10.6 CEBPA FLT3 JAK2 KIT KRAS RUNX1
41 peroxisome biogenesis disorder 7a 10.6 ETV6 FLT3 GATA2 JAK2 KIT RUNX1
42 glycogen storage disease type 0 10.6 CEBPA FLT3 IDH1 IDH2 NPM1
43 colorectal adenoma 10.6 DNMT3A ETV6 FLT3 JAK2 RUNX1
44 actinobacillosis 10.6 ETV6 FLT3 JAK2 KIT RUNX1
45 amblyopia 10.6 ETV6 FLT3 JAK2 PICALM RUNX1
46 unilateral hemispheric polymicrogyria 10.6 CEBPA FLT3 KIT RUNX1
47 adducted thumbs dundar type 10.6 ETV6 FLT3 KIT RUNX1
48 medullary cystic kidney disease 1 10.6 FLT3 GATA2 KRAS RUNX1
49 mild canavan disease 10.6 CEBPA GATA2 TGM6
50 neurofibromatosis 10.6 FLT3 KIT NPM1

Graphical network of the top 20 diseases related to Leukemia, Acute Myeloid:



Diseases related to Leukemia, Acute Myeloid

Symptoms & Phenotypes for Leukemia, Acute Myeloid

Symptoms by clinical synopsis from OMIM:

601626

Clinical features from OMIM:

601626

Human phenotypes related to Leukemia, Acute Myeloid:

32
id Description HPO Frequency HPO Source Accession
1 acute myeloid leukemia 32 HP:0004808

UMLS symptoms related to Leukemia, Acute Myeloid:


angina pectoris, chest pain, edema

MGI Mouse Phenotypes related to Leukemia, Acute Myeloid:

44 (show all 15)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.38 LPP NPM1 NUP214 PICALM RUNX1 TERT
2 growth/size/body region MP:0005378 10.31 CEBPA DNMT3A ETV6 FLT3 GATA2 IDH1
3 homeostasis/metabolism MP:0005376 10.3 RUNX1 TERT TGM6 IDH1 JAK2 KIT
4 hematopoietic system MP:0005397 10.26 CEBPA ETV6 FLT3 GATA2 IDH1 JAK2
5 mortality/aging MP:0010768 10.25 IDH1 JAK2 KIT KRAS LPP NPM1
6 embryo MP:0005380 10.22 DNMT3A ETV6 GATA2 JAK2 KIT KRAS
7 endocrine/exocrine gland MP:0005379 10.21 CEBPA DNMT3A ETV6 FLT3 GATA2 JAK2
8 cardiovascular system MP:0005385 10.2 ETV6 GATA2 IDH2 KIT KRAS NPM1
9 immune system MP:0005387 10.17 CEBPA ETV6 FLT3 IDH1 JAK2 KIT
10 integument MP:0010771 10.06 CEBPA CHIC2 ETV6 JAK2 KIT KRAS
11 liver/biliary system MP:0005370 9.97 CEBPA GATA2 JAK2 KIT KRAS NPM1
12 neoplasm MP:0002006 9.96 CEBPA ETV6 FLT3 IDH2 JAK2 KIT
13 no phenotypic analysis MP:0003012 9.76 ETV6 FLT3 KIT KRAS MLLT10 RUNX1
14 normal MP:0002873 9.56 CEBPA ETV6 GATA2 JAK2 KIT KRAS
15 skeleton MP:0005390 9.28 FLT3 IDH1 IDH2 JAK2 KIT KRAS

Drugs & Therapeutics for Leukemia, Acute Myeloid

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Leukine 17 SARGRAMOSTIM Immunex Approved on November 24, 1995/ Approved November 1996
2
Lynparza 17 46 OLAPARIB AstraZeneca Approved December 2014
3
Mylotarg 17 46 GEMTUZUMAB OZOGAMICIN Wyeth Approved May 2000
4
Neupogen 17 46 FILGRASTIM Amgen Approval April 1998

Drugs for Leukemia, Acute Myeloid (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 651)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 147-94-4 6253
2
Idarubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58957-92-9 42890
3
Fludarabine Approved Phase 4,Phase 2,Phase 3,Phase 1 21679-14-1, 75607-67-9 30751
4
Vidarabine Approved Phase 4,Phase 3,Phase 2,Phase 1 24356-66-9 32326 21704
5
Daunorubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 20830-81-3 30323
6
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 65271-80-9 4212
7
Azacitidine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 320-67-2 9444
8
Decitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2353-33-5 451668
9
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1 33419-42-0 36462
10
Arsenic trioxide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 1327-53-3 518740
11
Topotecan Approved, Investigational Phase 4,Phase 2,Phase 1 119413-54-6, 123948-87-8 60700
12
Amsacrine Approved Phase 4,Phase 3,Phase 1,Phase 2 51264-14-3 2179
13
Aldesleukin Approved Phase 4,Phase 3,Phase 2,Phase 1 85898-30-2, 110942-02-4
14
Histamine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 75614-87-8, 51-45-6 774
15
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
16
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
17
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1 135968-09-1
18
Thiotepa Approved Phase 4,Phase 3,Phase 2,Phase 1 52-24-4 5453
19
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
20
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
21
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
22
Busulfan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 55-98-1 2478
23
Lenalidomide Approved Phase 4,Phase 3,Phase 2,Phase 1 191732-72-6 216326
24
Posaconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 171228-49-2 147912
25
Nicotine Approved Phase 4 54-11-5 942 89594
26
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 284461-73-0 216239 406563
27
Micafungin Approved, Investigational Phase 4,Phase 2 235114-32-6 3081921 477468
28
Tretinoin Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 302-79-4 5538
29
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59-30-3 6037
30
Niacin Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 59-67-6 938
31
Nicotinamide Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 98-92-0 936
32
Vitamin C Approved, Nutraceutical Phase 4,Phase 2,Phase 1 50-81-7 5785 54670067
33
Aclarubicin Investigational Phase 4,Phase 2,Phase 1 57576-44-0 451415
34 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
35 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
38 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
39 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
40 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
41 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
42 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
43 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
44 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1
45 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1
46 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
47 Hormones Phase 4,Phase 3,Phase 2,Phase 1
48 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
49 Imatinib Mesylate Phase 4,Phase 3,Phase 2,Phase 1 123596
50 topoisomerase I inhibitors Phase 4,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 2533)
id Name Status NCT ID Phase
1 Idarubicin at Different Dosages as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia Unknown status NCT02277847 Phase 4
2 AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy Unknown status NCT02024308 Phase 4
3 3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia Unknown status NCT01587430 Phase 4
4 Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation Unknown status NCT01806116 Phase 4
5 Efficacy of G-CSF-Priming in Elderly AML Patients Unknown status NCT00199147 Phase 4
6 Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission Unknown status NCT01901666 Phase 4
7 AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia Unknown status NCT00180128 Phase 4
8 Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic Unknown status NCT00196768 Phase 4
9 Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed NCT00488709 Phase 4
10 LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML) Completed NCT01041040 Phase 4
11 AML2003 - Standard-Therapy vs Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years Completed NCT00180102 Phase 4
12 Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years Completed NCT00464217 Phase 4
13 Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia Completed NCT01347996 Phase 4
14 AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients Completed NCT00180115 Phase 4
15 Treatment of Acute Myeloblastic Leukemia in Younger Patients Completed NCT00390715 Phase 4
16 SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia Completed NCT00487448 Phase 4
17 Therapy of Acute Myeloid Leukemia in Patients Over the Age of 60 : DA Versus Mitoxantrone With Intermittent AraC Completed NCT00180167 Phase 4
18 Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care Completed NCT00161668 Phase 4
19 Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With Leukemia Completed NCT00304447 Phase 4
20 Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115) Completed NCT00686543 Phase 4
21 A Study for Dacogen Treatment in Patients With Myelodysplastic Syndrome Completed NCT01041846 Phase 4
22 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4
23 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4
24 Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA) Completed NCT00465933 Phase 4
25 Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005) Completed NCT00408278 Phase 4
26 Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) Completed NCT00504764 Phase 4
27 Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AML Recruiting NCT02474290 Phase 4
28 Early Tapering of Immunosuppressive Agents to Immunomodulation to Improve Survival of AML Patients Recruiting NCT03150134 Phase 4
29 Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML Recruiting NCT02926586 Phase 4
30 Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT Recruiting NCT02027064 Phase 4
31 Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML Patients Recruiting NCT02267993 Phase 4
32 Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections Recruiting NCT02805946 Phase 4
33 Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia Recruiting NCT02618109 Phase 4
34 A Rollover Study to Provide Continued Treatment With Eltrombopag Recruiting NCT01957176 Phase 4
35 Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL Recruiting NCT01987297 Phase 4
36 Respiratory Viral Infections During Acute Myeloid Leukemia (AML)Chemotherapy Related Aplasia Active, not recruiting NCT01819792 Phase 4
37 Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Acute Myeloid Leukemia With t(8;21) Active, not recruiting NCT03026842 Phase 4
38 Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Active, not recruiting NCT01200355 Phase 4
39 A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia Enrolling by invitation NCT02200978 Phase 4
40 Plasmatic L-AScorbic Acid in MYelodyplastic Syndroms and Controls Not yet recruiting NCT02809222 Phase 4
41 King's Invasive Aspergillosis Study II Not yet recruiting NCT02875743 Phase 4
42 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor Not yet recruiting NCT02933333 Phase 4
43 A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT Not yet recruiting NCT03176849 Phase 4
44 Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT) Not yet recruiting NCT01339988 Phase 4
45 LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML) Terminated NCT01198054 Phase 4
46 the Effects and Safety of Idarubicin-strengthened Pretreatment Program and Conventional Busulfan Cyclophosphamide Pretreatment Program on High-risk Acute Myeloid Leukemia Patient Unknown status NCT01766375 Phase 3
47 A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia Unknown status NCT01303796 Phase 3
48 Therapeutic Effect and Safety Study of Decitabine in Elderly Acute Myeloid Leukemia Patients Unknown status NCT01633099 Phase 3
49 Randomised Prospective Comparison of the NMA Allograft and the Traditional Allograft in Acute Myeloid Leukaemia Unknown status NCT00224614 Phase 3
50 Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia Unknown status NCT00002658 Phase 3

Search NIH Clinical Center for Leukemia, Acute Myeloid

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Leukemia, Acute Myeloid cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: leukemia, myeloid, acute

Genetic Tests for Leukemia, Acute Myeloid

Genetic tests related to Leukemia, Acute Myeloid:

id Genetic test Affiliating Genes
1 Acute Myeloid Leukemia 29 24 GATA2 GMPS MLF1 LPP CHEK2 KIT TERT NPM1 NSD1 NSD3 JAK2 NUP214 PICALM ARHGEF12 ETV6 FLT3 CBFB IDH1 IDH2 WT1 NRAS RUNX1
2 Leukemia, Acute Myeloid, Susceptibility to 29
3 Leukemia, Acute Myelogenous 24 KRAS

Anatomical Context for Leukemia, Acute Myeloid

MalaCards organs/tissues related to Leukemia, Acute Myeloid:

39
Myeloid, Bone, Bone Marrow, Neutrophil, Testes, Monocytes, Skin
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Leukemia, Acute Myeloid:
id Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Common Myeloid Progenitor Cells Affected by disease
2 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate

Publications for Leukemia, Acute Myeloid

Articles related to Leukemia, Acute Myeloid:

id Title Authors Year
1
MHC Class I Chain-Related Gene A (MICA) Donor-Recipient Mismatches and MICA-129 Polymorphism in Unrelated Donor Hematopoietic Cell Transplantations Has No Impact on Outcomes in Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome: A Center for International Blood and Marrow Transplant Research Study. ( 27987385 )
2016
2
The potential for dasatinib in treating chronic lymphocytic leukemia, acute myeloid leukemia, and myeloproliferative neoplasms. ( 21463117 )
2011
3
Concomitant chronic lymphocytic leukemia, acute myeloid leukemia, and thrombosis with protein C deficiency. Case report and review of the literature. ( 2646007 )
1989

Variations for Leukemia, Acute Myeloid

UniProtKB/Swiss-Prot genetic disease variations for Leukemia, Acute Myeloid:

66
id Symbol AA change Variation ID SNP ID
1 CEBPA p.His84Leu VAR_072677 rs28931590
2 JAK2 p.Lys607Asn VAR_032696 rs121912472
3 JAK2 p.Val617Phe VAR_032697 rs77375493
4 SETBP1 p.Gly870Ser VAR_063809 rs267607040
5 SETBP1 p.Ser854Ala VAR_069848
6 SETBP1 p.Gly870Arg VAR_069854
7 SETBP1 p.Ile871Ser VAR_069856

ClinVar genetic disease variations for Leukemia, Acute Myeloid:

6 (show top 50) (show all 209)
id Gene Variation Type Significance SNP ID Assembly Location
1 ETV6 NM_001987.4(ETV6): c.226G> T (p.Glu76Ter) single nucleotide variant Pathogenic rs121434637 GRCh37 Chromosome 12, 11992136: 11992136
2 ETV6 NM_001987.4(ETV6): c.1307_1308insGGG (p.His436delinsGlnGly) insertion Pathogenic rs587776710 GRCh37 Chromosome 12, 12043928: 12043929
3 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic/Likely pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
4 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
5 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
6 KRAS NM_033360.3(KRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic/Likely pathogenic rs112445441 GRCh37 Chromosome 12, 25398281: 25398281
7 KRAS NM_004985.4(KRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913529 GRCh37 Chromosome 12, 25398284: 25398284
8 KRAS NM_004985.4(KRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913529 GRCh37 Chromosome 12, 25398284: 25398284
9 KRAS NM_004985.4(KRAS): c.27_29dupTGG (p.Gly10_Ala11insGly) duplication Pathogenic rs606231202 GRCh38 Chromosome 12, 25245356: 25245358
10 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
11 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic/Likely pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
12 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
13 HRAS NM_005343.3(HRAS): c.436G> A (p.Ala146Thr) single nucleotide variant Pathogenic/Likely pathogenic rs104894231 GRCh37 Chromosome 11, 533467: 533467
14 HRAS NM_005343.3(HRAS): c.437C> T (p.Ala146Val) single nucleotide variant Pathogenic/Likely pathogenic rs121917759 GRCh37 Chromosome 11, 533466: 533466
15 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
16 KIT NM_000222.2(KIT): c.2447A> T (p.Asp816Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913507 GRCh37 Chromosome 4, 55599321: 55599321
17 KIT NM_000222.2(KIT): c.2446G> T (p.Asp816Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913506 GRCh37 Chromosome 4, 55599320: 55599320
18 KIT NM_000222.2(KIT): c.2446G> C (p.Asp816His) single nucleotide variant Pathogenic/Likely pathogenic rs121913506 GRCh37 Chromosome 4, 55599320: 55599320
19 NRAS NM_002524.4(NRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121434595 GRCh37 Chromosome 1, 115258745: 115258745
20 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
21 NRAS NM_002524.4(NRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121434596 GRCh37 Chromosome 1, 115258744: 115258744
22 NPM1 NM_002520.6(NPM1): c.860_863dupTCTG (p.Trp288Cysfs) duplication Pathogenic rs587776806 GRCh38 Chromosome 5, 171410540: 171410543
23 NPM1 NM_002520.6(NPM1): c.863_864insCATG (p.Trp288Cysfs) insertion Pathogenic rs587776806 GRCh38 Chromosome 5, 171410543: 171410544
24 NPM1 NM_002520.6(NPM1): c.863_864insCGTG (p.Trp288Cysfs) insertion Pathogenic rs587776806 GRCh38 Chromosome 5, 171410543: 171410544
25 NPM1 NM_002520.6(NPM1): c.863_864insCCTG (p.Trp288Cysfs) insertion Pathogenic rs587776806 GRCh38 Chromosome 5, 171410543: 171410544
26 JAK2 NM_004972.3(JAK2): c.1849G> T (p.Val617Phe) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs77375493 GRCh37 Chromosome 9, 5073770: 5073770
27 JAK2 NM_004972.3(JAK2): c.1821G> C (p.Lys607Asn) single nucleotide variant Pathogenic rs121912472 GRCh37 Chromosome 9, 5073742: 5073742
28 IDH2 NM_002168.3(IDH2): c.419G> A (p.Arg140Gln) single nucleotide variant Pathogenic/Likely pathogenic rs121913502 GRCh37 Chromosome 15, 90631934: 90631934
29 FLT3 NM_004119.2(FLT3): c.2520_2521insGGATCC (p.Ser840_Asn841insGlySer) insertion Pathogenic rs398122514 GRCh37 Chromosome 13, 28592624: 28592625
30 FLT3 NM_004119.2(FLT3): c.2504A> T (p.Asp835Val) single nucleotide variant Pathogenic rs121909646 GRCh37 Chromosome 13, 28592641: 28592641
31 FLT3 NM_004119.2(FLT3): c.2503G> C (p.Asp835His) single nucleotide variant Pathogenic rs121913488 GRCh37 Chromosome 13, 28592642: 28592642
32 FLT3 NM_004119.2(FLT3): c.2503G> A (p.Asp835Asn) single nucleotide variant Pathogenic rs121913488 GRCh37 Chromosome 13, 28592642: 28592642
33 FLT3 FLT3, ASP835GLU undetermined variant Pathogenic
34 FLT3 NM_004119.2(FLT3): c.2503G> T (p.Asp835Tyr) single nucleotide variant Pathogenic rs121913488 GRCh37 Chromosome 13, 28592642: 28592642
35 FLT3 NM_004119.2(FLT3): c.2503_2505delGAT (p.Asp835del) deletion Pathogenic/Likely pathogenic rs121913486 GRCh37 Chromosome 13, 28592640: 28592642
36 CEBPA NM_004364.4(CEBPA): c.115_121delCCCGCGC (p.Pro39Serfs) deletion Pathogenic rs587776848 GRCh38 Chromosome 19, 33302294: 33302300
37 CEBPA NM_004364.4(CEBPA): c.148G> T (p.Glu50Ter) single nucleotide variant Pathogenic rs121912791 GRCh37 Chromosome 19, 33793173: 33793173
38 CEBPA NM_004364.4(CEBPA): c.251A> T (p.His84Leu) single nucleotide variant Pathogenic rs28931590 GRCh37 Chromosome 19, 33793070: 33793070
39 CEBPA NM_004364.4(CEBPA) duplication Pathogenic GRCh38 Chromosome 19, 33301424: 33301480
40 CEBPA NM_004364.4(CEBPA) duplication Pathogenic GRCh38 Chromosome 19, 33301464: 33301490
41 CEBPA NM_004364.4(CEBPA): c.211_214dupGCCG (p.Ala72Glyfs) duplication Pathogenic rs587776849 GRCh38 Chromosome 19, 33302201: 33302204
42 CEBPA NM_004364.4(CEBPA): c.68delC (p.Pro23Argfs) deletion Pathogenic rs137852728 GRCh38 Chromosome 19, 33302347: 33302347
43 CEBPA NM_004364.4(CEBPA): c.141delC (p.Ala48Profs) deletion Pathogenic rs137852730 GRCh37 Chromosome 19, 33793180: 33793180
44 CEBPA NM_004364.4(CEBPA): c.198_201dupCTAC (p.Ile68Leufs*41) duplication Pathogenic rs137852731 GRCh37 Chromosome 19, 33793120: 33793123
45 CEBPA NM_004364.4(CEBPA): c.217_218insC (p.Phe73Serfs) insertion Pathogenic rs137852733 GRCh37 Chromosome 19, 33793103: 33793104
46 CEBPA NM_004364.4(CEBPA): c.318_319dupTG (p.Asp107Valfs*54) duplication Pathogenic rs137852732 GRCh37 Chromosome 19, 33793002: 33793003
47 CEBPA NM_004364.4(CEBPA): c.68dupC (p.His24Alafs) duplication Pathogenic rs137852729 GRCh37 Chromosome 19, 33793253: 33793253
48 GATA2 NM_001145661.1(GATA2): c.1192C> T (p.Arg398Trp) single nucleotide variant Pathogenic/Likely pathogenic rs387906629 GRCh37 Chromosome 3, 128200113: 128200113
49 GATA2 NM_001145661.1(GATA2): c.1061C> T (p.Thr354Met) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs387906631 GRCh37 Chromosome 3, 128200744: 128200744
50 TGM6 NM_198994.2(TGM6): c.1550T> G (p.Leu517Trp) single nucleotide variant Pathogenic rs387907097 GRCh37 Chromosome 20, 2398091: 2398091

Copy number variations for Leukemia, Acute Myeloid from CNVD:

7 (show top 50) (show all 491)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13336 1 1 124300000 Insertion Acute myeloid leukemia
2 13759 1 1 28000000 Deletion Acute myeloid leukemia
3 14790 1 110122000 110569000 Gain or loss Acute myeloid leukemia
4 17466 1 142902432 245422360 Duplication Acute myeloid leukemia
5 18096 1 143961000 247125000 Gain or loss Acute myeloid leukemia
6 20826 1 154656757 154656845 Amplification Acute myeloid leukemia
7 24589 1 182359000 182787000 Loss Acute myeloid leukemia
8 26098 1 197094625 197094734 Amplification Acute myeloid leukemia
9 26100 1 197094796 197094905 Amplification Acute myeloid leukemia
10 27148 1 204981000 205049000 Gain or loss Acute myeloid leukemia
11 27263 1 206041820 206041907 Amplification Acute myeloid leukemia
12 27859 1 214500000 224100000 Deletion Acute myeloid leukemia
13 28491 1 222606000 222909000 Gain or loss Acute myeloid leukemia
14 29341 1 230606000 230646000 Gain or loss Acute myeloid leukemia
15 32943 1 40683565 40683656 Amplification Acute myeloid leukemia
16 32944 1 40686494 40686582 Amplification Acute myeloid leukemia
17 33084 1 42072000 42456000 Gain or loss Acute myeloid leukemia
18 35033 1 5913000 7696000 Gain or loss Acute myeloid leukemia
19 35608 1 65296705 65296779 Amplification Acute myeloid leukemia
20 35769 1 67074000 69951000 Gain or loss Acute myeloid leukemia
21 36085 1 71305902 71305987 Amplification miR-186 Acute myeloid leukemia
22 38187 10 1 6700000 Insertion IL15RA Acute myeloid leukemia
23 38188 10 1 6700000 Insertion PRKCQ Acute myeloid leukemia
24 38677 10 104186259 104186331 Deletion Acute myeloid leukemia
25 38804 10 105144000 105144148 Deletion Acute myeloid leukemia
26 39144 10 110889374 110889450 Deletion Acute myeloid leukemia
27 39902 10 122017230 122017301 Deletion let-7a-2 Acute myeloid leukemia
28 41668 10 21893278 22027081 Loss MLLT10 Acute myeloid leukemia
29 41990 10 27075530 27189965 Translate SSH3BP1 Acute myeloid leukemia
30 43278 10 46100000 49900000 Copy number GDF10 Acute myeloid leukemia
31 44445 10 57165247 57165335 Deletion Acute myeloid leukemia
32 44874 11 64658609 64658718 Deletion miR-192 Acute myeloid leukemia
33 45369 10 70521000 135283000 Gain Acute myeloid leukemia
34 47681 10 96486000 100815000 Loss Acute myeloid leukemia
35 49592 11 108316750 133951370 Triplication Acute myeloid leukemia
36 50142 11 114500000 121200000 Copy number MLL Acute myeloid leukemia
37 50190 11 115400000 120700000 Insertion DDX6 Acute myeloid leukemia
38 50191 11 115400000 120700000 Insertion ETS1 Acute myeloid leukemia
39 50192 11 115400000 120700000 Insertion FLI1 Acute myeloid leukemia
40 50193 11 115400000 120700000 Insertion MLL Acute myeloid leukemia
41 50261 11 116297361 116448564 Loss Acute myeloid leukemia
42 50346 11 117203762 118563610 Amplification Acute myeloid leukemia
43 50385 11 117603158 117860329 Duplication Acute myeloid leukemia
44 50437 11 117820656 117856311 Gain MLL Acute myeloid leukemia
45 50640 11 118585028 127052111 Deletion Acute myeloid leukemia
46 51468 11 126537000 130235000 Gain Acute myeloid leukemia
47 51512 11 127394408 133951311 Amplification Acute myeloid leukemia
48 52810 11 2016406 2019065 Methylation H19 Acute myeloid leukemia
49 53744 11 32409321 32457081 Mutation WT1 Acute myeloid leukemia
50 54217 11 39671000 39746000 Loss Acute myeloid leukemia

Expression for Leukemia, Acute Myeloid

Search GEO for disease gene expression data for Leukemia, Acute Myeloid.

Pathways for Leukemia, Acute Myeloid

Pathways related to Leukemia, Acute Myeloid according to KEGG:

37
id Name Kegg Source Accession
1 Acute myeloid leukemia hsa05221

GO Terms for Leukemia, Acute Myeloid

Cellular components related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.85 CEBPA DNMT3A GATA2 JAK2 MLLT10 NPM1
2 nucleus GO:0005634 9.8 CEBPA DNMT3A ETV6 FLT3 GATA2 JAK2
3 focal adhesion GO:0005925 9.02 JAK2 KRAS LPP NPM1 NUP214

Biological processes related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

(show all 16)
id Name GO ID Score Top Affiliating Genes
1 transcription from RNA polymerase II promoter GO:0006366 9.95 CEBPA ETV6 GATA2 NPM1 RUNX1
2 positive regulation of cell proliferation GO:0008284 9.88 FLT3 JAK2 KIT KRAS NPM1
3 mitochondrion organization GO:0007005 9.67 CEBPA IDH2 TERT
4 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.61 FLT3 JAK2 KIT
5 positive regulation of MAP kinase activity GO:0043406 9.58 FLT3 KIT KRAS
6 2-oxoglutarate metabolic process GO:0006103 9.56 IDH1 IDH2
7 positive regulation of tyrosine phosphorylation of Stat5 protein GO:0042523 9.54 JAK2 KIT
8 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.52 JAK2 TERT
9 hematopoietic stem cell proliferation GO:0071425 9.51 ETV6 RUNX1
10 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.5 FLT3 JAK2 KIT
11 negative regulation of glial cell proliferation GO:0060253 9.46 IDH2 TERT
12 myeloid progenitor cell differentiation GO:0002318 9.37 FLT3 KIT
13 cytokine-mediated signaling pathway GO:0019221 9.35 CEBPA FLT3 JAK2 KIT KRAS
14 isocitrate metabolic process GO:0006102 9.26 IDH1 IDH2
15 glyoxylate cycle GO:0006097 9.16 IDH1 IDH2
16 hemopoiesis GO:0030097 9.02 FLT3 GATA2 KIT PICALM RUNX1

Molecular functions related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 metal ion binding GO:0046872 9.93 DNMT3A GATA2 IDH1 IDH2 JAK2 KIT
2 protein homodimerization activity GO:0042803 9.8 CEBPA FLT3 IDH1 KIT NPM1 TERT
3 isocitrate dehydrogenase (NADP+) activity GO:0004450 8.96 IDH1 IDH2
4 isocitrate dehydrogenase activity GO:0004448 8.62 IDH1 IDH2
5 protein binding GO:0005515 10.19 CEBPA CHIC2 DNMT3A ETV6 FLT3 GATA2

Sources for Leukemia, Acute Myeloid

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....